Stock listing
Inhibrx Biosciences, Inc.
Selected listing: INBX · NASDAQ · USD · US
Inhibrx Biosciences, Inc. (NASDAQ:INBX), Health Technology. Latest release Sep 8, 2026: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim…
- Ticker
- NASDAQ:INBX
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a public company traded under the ticker INBX on the American market. Inhibrx focuses on developing innovative therapies to address unmet medical needs.
Latest news from Inhibrx Biosciences, Inc.
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
September 8, 2026
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
September 4, 2026
Inhibrx Reports Second Quarter 2026 Financial Results
August 13, 2026
Inhibrx Biosciences : Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
July 16, 2026
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
June 15, 2026
Research Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. company profile
View the public company page for Inhibrx Biosciences, Inc. on 6ix.
Inhibrx Biosciences, Inc. news
Read company news and market updates connected to Inhibrx Biosciences, Inc..
Inhibrx Biosciences, Inc. investor events
Find investor webinars, events, and replay context for Inhibrx Biosciences, Inc..